Lance A. Thielen

636 total citations
8 papers, 495 citations indexed

About

Lance A. Thielen is a scholar working on Surgery, Molecular Biology and Cell Biology. According to data from OpenAlex, Lance A. Thielen has authored 8 papers receiving a total of 495 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Surgery, 4 papers in Molecular Biology and 3 papers in Cell Biology. Recurrent topics in Lance A. Thielen's work include Pancreatic function and diabetes (5 papers), Diabetes and associated disorders (3 papers) and Endoplasmic Reticulum Stress and Disease (3 papers). Lance A. Thielen is often cited by papers focused on Pancreatic function and diabetes (5 papers), Diabetes and associated disorders (3 papers) and Endoplasmic Reticulum Stress and Disease (3 papers). Lance A. Thielen collaborates with scholars based in United States. Lance A. Thielen's co-authors include Anath Shalev, Guanlan Xu, Truman Grayson, Peng Li, Tiffany Grimes, Fernando Ovalle, Junqin Chen, Matt Kanke, Praveen Sethupathy and Hubert M. Tse and has published in prestigious journals such as Nature Medicine, Nature Communications and Cell Metabolism.

In The Last Decade

Lance A. Thielen

8 papers receiving 487 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lance A. Thielen United States 6 277 200 190 183 67 8 495
Wan-Ru Lee United States 12 186 0.7× 276 1.4× 72 0.4× 78 0.4× 59 0.9× 12 515
Vaibhav Sidarala United States 10 210 0.8× 221 1.1× 76 0.4× 83 0.5× 19 0.3× 19 399
Ebru Boslem Australia 10 342 1.2× 326 1.6× 149 0.8× 112 0.6× 41 0.6× 12 704
Aaron Bender United States 9 400 1.4× 292 1.5× 216 1.1× 272 1.5× 19 0.3× 11 616
Victoria South United States 5 189 0.7× 263 1.3× 290 1.5× 56 0.3× 70 1.0× 8 655
M.M. McGrane United States 9 120 0.4× 389 1.9× 172 0.9× 237 1.3× 32 0.5× 10 629
Kristan Melford United States 11 148 0.5× 224 1.1× 418 2.2× 125 0.7× 137 2.0× 14 831
Carina Cardalda Argentina 7 512 1.8× 306 1.5× 205 1.1× 306 1.7× 29 0.4× 9 697
Miwon Ahn United States 12 120 0.4× 209 1.0× 57 0.3× 54 0.3× 62 0.9× 23 383
Marie-Hélène Cuif France 6 304 1.1× 330 1.6× 142 0.7× 81 0.4× 64 1.0× 8 516

Countries citing papers authored by Lance A. Thielen

Since Specialization
Citations

This map shows the geographic impact of Lance A. Thielen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lance A. Thielen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lance A. Thielen more than expected).

Fields of papers citing papers by Lance A. Thielen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lance A. Thielen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lance A. Thielen. The network helps show where Lance A. Thielen may publish in the future.

Co-authorship network of co-authors of Lance A. Thielen

This figure shows the co-authorship network connecting the top 25 collaborators of Lance A. Thielen. A scholar is included among the top collaborators of Lance A. Thielen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lance A. Thielen. Lance A. Thielen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Xu, Guanlan, Tiffany Grimes, Truman Grayson, et al.. (2022). Exploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type 1 diabetes. Nature Communications. 13(1). 1159–1159. 49 indexed citations
2.
Thielen, Lance A., Junqin Chen, Jing Gu, et al.. (2020). Identification of an Anti-diabetic, Orally Available Small Molecule that Regulates TXNIP Expression and Glucagon Action. Cell Metabolism. 32(3). 353–365.e8. 81 indexed citations
3.
Xu, Guanlan, Lance A. Thielen, Junqin Chen, et al.. (2019). Serum miR-204 is an early biomarker of type 1 diabetes-associated pancreatic beta-cell loss. American Journal of Physiology-Endocrinology and Metabolism. 317(4). E723–E730. 35 indexed citations
4.
Ovalle, Fernando, Tiffany Grimes, Guanlan Xu, et al.. (2018). Verapamil and beta cell function in adults with recent-onset type 1 diabetes. Nature Medicine. 24(8). 1108–1112. 171 indexed citations
5.
Thielen, Lance A. & Anath Shalev. (2018). Diabetes pathogenic mechanisms and potential new therapies based upon a novel target called TXNIP. Current Opinion in Endocrinology Diabetes and Obesity. 25(2). 75–80. 85 indexed citations
6.
Thielen, Lance A., et al.. (2018). Novel Small Molecule TXNIP Inhibitor Protects Against Diabetes. Diabetes. 67(Supplement_1). 3 indexed citations
7.
Xu, Guanlan, et al.. (2018). GDF15 Is Induced by T1D-Associated Cytokines and ER Stress and Promotes Beta-Cell Apoptosis. Diabetes. 67(Supplement_1). 2 indexed citations
8.
Chen, Junqin, et al.. (2017). miR-204 Controls Glucagon-Like Peptide 1 Receptor Expression and Agonist Function. Diabetes. 67(2). 256–264. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026